FINWIRES · TerminalLIVE
FINWIRES

Racura Oncology Receives Clearance to Advance Dose Level in Phase One Cardioprotection, Anticancer Synergy Trial

By

Racura Oncology (ASX:RAC) received clearance from the Safety Review Committee to advance the RC220 dose in the first-phase Cardioprotection and Anticancer Synergy trial to the next designated dose level of 80 milligrams per square meter, according to a Friday filing with the Australian bourse.

RC220 is the company's formulation of the anticancer agent (E,E)-bisantrene.

The approval comes following confirmation that the drug showed an acceptable safety profile, with no dose-limiting toxicities or safety concerns noted during the observation period for the first three group one patients dosed at 40 milligrams per square meter, the filing said.

Related Articles

Asia

Market Chatter: IMF Welcomes US-China Dialogue; Warns Middle East Conflict Slowing Global Growth

The International Monetary Fund praised the productive talks between Donald Trump and Xi Jinping, noting that easing trade friction between the world's two biggest economies would support worldwide economic health, Reuters reported Friday.Spokesperson Julie Kozack emphasized that lowering trade tensions and uncertainty serves the interests of both nations and the broader global market, according to the report.Kozack also cautioned that the ongoing conflict in the Middle East, which is keeping crude prices over $100 per barrel, is steering the world economy into the IMF's "adverse" projection, slashing global growth to 2.5% versus the expected 3.1%, Reuters wrote.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^SSEC$^SZSE
Asia

Market Chatter: Russia's Putin to Visit China

Russia's President Vladimir Putin is set to visit China very soon, Reuters reported Thursday, citing ​Kremlin spokesman Dmitry Peskov.Putin and Chinese President Xi Jinping, who have met over 40 times through the years, signed a "no limits" strategic partnership in February 2022, according to the report.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^SSEC$^SZSE
Asia

Electro Optic Systems Amends Terms for Acquisition of MARSS Group Assets, Shares Jump 7%

Electro Optic Systems Holdings (ASX:EOS) agreed revised agreement terms for its acquisition of the assets of the MARSS group business, according to a Friday Australian bourse filing.The upfront payment of $36 million for MARSS will be made on Friday, and the receipt of the funds by the MARSS vendors and the completion of the acquisition are expected in the coming days, per the filing.The maximum earnout cap under the agreement will be increased to 140 million euros from 100 million euros.Electro Optic drew AU$70 million of its term loan facility provided by Washington H. Soul Pattinson. AU$50 million of the drawdown will be used to fund the upfront cash consideration.MARSS' NiDAR command and control systems are used to detect, track, and defeat drone attacks. The acceleration of potential demand and increased interest in the MARSS products and business led to certain amendments to the transaction terms first disclosed on Jan. 12.Its shares jumped 7% in recent trading on Friday.

$ASX:EOS